Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 1;34(4):417-421.
doi: 10.1097/MEG.0000000000002255.

Selective internal radiation therapy in older patients with hepatocellular carcinoma: a retrospective analysis

Soraya Benguerfi  1 , Florian Estrade  1 , Céline Lescure  1 , Yan Rolland  2 , Xavier Palard  3 , Samuel Le Sourd  1 , Marc Pracht  1 , Héloïse Bourien  1 , Léa Muzellec  1 , Fanny Le Du  1 , Etienne Garin  3 , Julien Edeline  1
Affiliations

Selective internal radiation therapy in older patients with hepatocellular carcinoma: a retrospective analysis

Soraya Benguerfi et al. Eur J Gastroenterol Hepatol. .

Abstract

Background: Selective internal radiation therapy (SIRT) is applied to hepatocellular carcinoma (HCC), a disease with increased incidence in the elderly. However, SIRT has rarely been specifically studied in elderly population. The aim of this study was to investigate efficacy and safety of SIRT in elderly HCC patients.

Methods: We studied retrospectively data from patients treated with SIRT for HCC. Clinical and laboratory data were retrieved. We used 70-years old as threshold between younger and elderly populations, to compare outcomes.

Results: A total of 222 patients treated with SIRT for HCC were studied, of which 134 patients were younger and 88 older. Median overall survival (OS) was not significantly different between younger and elderly group: 15.6 months (95% CI, 11.7-19.5) and 14.8 months (95% CI, 9.4-20.3) (P = 0.86). Age was not associated with OS in multivariable analysis, with a Hazard ratio of 1.09 (95% CI, 0.82-1.45, P = 0.55). Results of progression-free survival and responses were also similar in both groups. Toxicities were similar between the two groups, including the occurrence of radioembolization-induced liver disease (11.5 vs. 11.4%, P = 0.97).

Conclusion: SIRT appears to be a well-tolerated treatment with the same efficacy in elderly compared to younger patients in HCC. Our study is the first to study its impact with glass microspheres. This warrants confirmation in large prospective studies.

PubMed Disclaimer

References

    1. Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, et alGlobal Burden of Disease Cancer Collaboration;. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol 2019; 5:1749–1768.
    1. Fulop T, Kotb R, Fortin CF, Pawelec G, de Angelis F, Larbi A. Potential role of immunosenescence in cancer development. Ann N Y Acad Sci 2010; 1197:158–165.
    1. Yancik R, Ries LA. Cancer in older persons: an international issue in an aging world. Semin Oncol 2004; 31:128–136.
    1. Geriatric Oncology. OncologyPRO [Internet]. [Cited 2020 May 11]. https://oncologypro.esmo.org/oncology-in-practice/cancer-in-special-situ...
    1. Llovet JM, Fuster J, Bruix J; Barcelona-Clínic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10(2 Suppl):S115–S120. 2016. https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/lt.20034 [Accessed 6 July 2021] - DOI

Substances